Boston Scientific Narrowing Gap With J&J In European DES Market
This article was originally published in The Gray Sheet
Executive Summary
Boston Scientific's Taxus stent is on track to claim half of the European drug-eluting stent market from rival and first-mover Johnson & Johnson/Cordis over the next several months, the firm says
You may also be interested in...
J&J Forecasts Quicker EU Conversion To Cypher In Wake Of FDA Sign-Off
U.S. approval of Johnson & Johnson/Cordis' Cypher sirolimus-eluting stent will exert pressure on key European markets to pay for the device despite its significant price premium over conventional coronary stents, the company asserts
There’s ‘No Silver Bullet’ For Making Medicines Packaging Sustainable
There’s no simple answer to the question of how to make medicines packaging sustainable, says international recycling consultancy and Veolia Group subsidiary Circpack. “Manufacturers need to assess what works best for them, and recyclers will do the same,” Circpack analyst and circular packaging expert Filipe Vieira de Castro tells HBW Insight in this exclusive Q&A. “The best thing we can all do is put effort into finding common ground between systems, which comes down to better understanding the complexities between them.”
Entries Begin To Roll In For 2024 Industry Awards
Entries have now begun rolling in for the Global Generics & Biosimilars Awards, which returns to Milan this October, Free to enter and attend, the ceremony recognizes the top achievements across the generics, biosimilars and value added medicines industries.